TY - JOUR
T1 - A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma
AU - Radhakrishnan, Aneesha
AU - Nanjappa, Vishalakshi
AU - Raja, Remya
AU - Sathe, Gajanan
AU - Puttamallesh, Vinuth N.
AU - Jain, Ankit P.
AU - Pinto, Sneha M.
AU - Balaji, Sai A.
AU - Chavan, Sandip
AU - Sahasrabuddhe, Nandini A.
AU - Mathur, Premendu P.
AU - Kumar, Mahesh M.
AU - Prasad, T. S.Keshava
AU - Santosh, Vani
AU - Sukumar, Geethanjali
AU - Califano, Joseph A.
AU - Rangarajan, Annapoorni
AU - Sidransky, David
AU - Pandey, Akhilesh
AU - Gowda, Harsha
AU - Chatterjee, Aditi
N1 - Publisher Copyright:
© The Author(s) 2016.
PY - 2016/10/31
Y1 - 2016/10/31
N2 - Despite advances in clinical management, 5-year survival rate in patients with late-stage head and neck squamous cell carcinoma (HNSCC) has not improved significantly over the past decade. Targeted therapies have emerged as one of the most promising approaches to treat several malignancies. Though tyrosine phosphorylation accounts for a minority of total phosphorylation, it is critical for activation of signaling pathways and plays a significant role in driving cancers. To identify activated tyrosine kinase signaling pathways in HNSCC, we compared the phosphotyrosine profiles of a panel of HNSCC cell lines to a normal oral keratinocyte cell line. Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) was one of the kinases hyperphosphorylated at Tyr-321 in all HNSCC cell lines. Inhibition of DYRK1A resulted in an increased apoptosis and decrease in invasion and colony formation ability of HNSCC cell lines. Further, administration of the small molecular inhibitor against DYRK1A in mice bearing HNSCC xenograft tumors induced regression of tumor growth. Immunohistochemical labeling of DYRK1A in primary tumor tissues using tissue microarrays revealed strong to moderate staining of DYRK1A in 97.5% (39/40) of HNSCC tissues analyzed. Taken together our results suggest that DYRK1A could be a novel therapeutic target in HNSCC.
AB - Despite advances in clinical management, 5-year survival rate in patients with late-stage head and neck squamous cell carcinoma (HNSCC) has not improved significantly over the past decade. Targeted therapies have emerged as one of the most promising approaches to treat several malignancies. Though tyrosine phosphorylation accounts for a minority of total phosphorylation, it is critical for activation of signaling pathways and plays a significant role in driving cancers. To identify activated tyrosine kinase signaling pathways in HNSCC, we compared the phosphotyrosine profiles of a panel of HNSCC cell lines to a normal oral keratinocyte cell line. Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) was one of the kinases hyperphosphorylated at Tyr-321 in all HNSCC cell lines. Inhibition of DYRK1A resulted in an increased apoptosis and decrease in invasion and colony formation ability of HNSCC cell lines. Further, administration of the small molecular inhibitor against DYRK1A in mice bearing HNSCC xenograft tumors induced regression of tumor growth. Immunohistochemical labeling of DYRK1A in primary tumor tissues using tissue microarrays revealed strong to moderate staining of DYRK1A in 97.5% (39/40) of HNSCC tissues analyzed. Taken together our results suggest that DYRK1A could be a novel therapeutic target in HNSCC.
UR - http://www.scopus.com/inward/record.url?scp=84993967667&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84993967667&partnerID=8YFLogxK
U2 - 10.1038/srep36132
DO - 10.1038/srep36132
M3 - Article
C2 - 27796319
AN - SCOPUS:84993967667
SN - 2045-2322
VL - 6
JO - Scientific reports
JF - Scientific reports
M1 - 36132
ER -